We’re welcoming 2025 by sharing highlights and milestones from our 38th year.

For many of us in the psychedelic community, 2024 will long be remembered as a challenging year. For us at MAPS and the countless people yearning for a new treatment option for PTSD, nothing is more painful than the FDA calling for more research before reconsidering the New Drug Application for MDMA-assisted therapy. The cascading impacts of this unexpected delay have forced us to make changes here at MAPS, but as we know, difficult is not the same as bad. 

We have reflected on these profound shifts and honed our focus on the most impactful work we can do to further our multidisciplinary mission. We’ve also seen the seeds we planted in years past sprout, strengthening our belief that diligent, committed work will lead to meaningful change, even if the timelines aren’t always according to plan. We’ve highlighted some of our favorite accomplishments and impacts of 2024 below — simply click on the boxes to learn more about them. 

In 2025, we look forward to forging transformative collaborations, educating people and communities, fostering novel research, and advancing psychedelic policy reforms toward healing and justice. The collective, interconnected web of MAPS and the psychedelic movement — people just like you — holds the seeds that, someday, will flower into safer, more equitable psychedelic access.

Thank you for being on this journey with us!

7

Psychedelic Research Studies Supported

29

Countries Represented in Therapist Education

24,582

Integration Workbooks Downloaded

3,000+

First Responders Trained

9

Fiscally Sponsored Organizations

72

Conference Presentations

6

Ecosystem Grants Awarded

23,354

Music is the Bridge Listeners

13

State Reform Efforts Impacted

5

Coalitions and Working Groups Supported

4

FDA Objections Overcome

35

Experts Joined MAPS’ Speakers Bureau

Timeline

MAPS PBC Becomes Lykos Therapeutics

MAPS now shares ownership of Lykos Therapeutics with mission-aligned investors, including philanthropic foundations and donor-advised funds

January 5

MAPS Unveils Improved Fiscal Sponsorship Program

To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movement

January 16

Psychedelic Science Announced for June 16-20

10+ stages, a city block of exhibitor space, dozens of workshops, and a whole universe of networking and social events planned in Denver, CO.

February 13

MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders

MAPS uses its over 30 years of experience to offer a gold-standard, first-of-its-kind training program.

March 11

FDA Calls for Additional Study of MDMA-assisted Therapy

Despite this significant setback, MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal.

August 9

Rick Responds to FDA’s Denial of MDMA Approval

In a personal note and video, Rick describes his disappointment in the FDA denial and what continues to give him hope.

August 16

MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial

Emory study is one of the first trials exploring whether psychedelic-assisted therapy can enhance an existing evidence-based PTSD therapeutic treatment

August 26

MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute

After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a trial to examine the use of smoked cannabis for the treatment of PTSD symptoms.

November 20

Thank you to all our supporters for your continued commitment to our shared mission in 2024.  We hope to see you in Denver at Psychedelic Science 2025!

All contributions will be used to further MAPS’ general mission purposes and may be reallocated to the areas of greatest need, urgency, and impact.